Akihito Yokoyama

Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials

Nicola A. Hanania, Phillip E. Korenblat, Kenneth R. Chapman et al. · The Lancet Respiratory Medicine · 2016 · 466 citations

Medicine, Internal Medicine, Pharmacology +10

Comparative Study of KL-6, Surfactant Protein-A, Surfactant Protein-D, and Monocyte Chemoattractant Protein-1 as Serum Markers for Interstitial Lung Diseases

Hiroshi Ohnishi, Akihito Yokoyama, Keiichi Kondo et al. · American Journal of Respiratory and Critical Care Medicine · 2002 · 405 citations

Medicine, Immunology, Pathology +17

Prognostic value of circulating KL‐6 in idiopathic pulmonary fibrosis

Akihito Yokoyama, Keiichi Kondo, Masamitsu Nakajima et al. · Respirology · 2006 · 308 citations

Medicine, Pathobiology, Pathology +15

KL-6, a Mucin-like Glycoprotein, in Bronchoalveolar Lavage Fluid from Patients with Interstitial Lung Disease

Nobuoki Kohno, Yukikazu Awaya, Tetsu Oyama et al. · American Review of Respiratory Disease · 1993 · 292 citations

Medicine, Immunology, Pathology +17

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo

Jing Yang, Takayuki Ikezoe, Chie Nishioka et al. · Blood · 2007 · 286 citations · Full text

Medicine, Oncology, Pharmacology +17